ro 11-2933 has been researched along with Leukemia P388 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Canti, G; Mazzoni, A | 1 |
| Bankusli, I; Mayhew, E; Radel, S; Rustum, YM | 1 |
2 other study(ies) available for ro 11-2933 and Leukemia P388
| Article | Year |
|---|---|
Reversal of doxorubicin and cisplatin resistance in vivo in murine leukemias by the calcium antagonist RO 11-2933.
Topics: Animals; Calcium Channel Blockers; Cisplatin; Doxorubicin; Drug Interactions; Drug Resistance; Drug Screening Assays, Antitumor; Female; Leukemia L1210; Leukemia P388; Mice; Mice, Inbred DBA; Neoplasm Transplantation; Propylamines | 1990 |
The effects of verapamil and a tiapamil analogue, DMDP, on adriamycin-induced cytotoxicity in P388 adriamycin-resistant and -sensitive leukemia in vitro and in vivo.
Topics: Animals; Calcium Channel Blockers; Doxorubicin; Drug Resistance; Drug Synergism; Female; Glycoproteins; Leukemia P388; Leukemia, Experimental; Mice; Mice, Inbred DBA; Propylamines; Tumor Cells, Cultured; Verapamil | 1988 |